


**AppCp**

(AMPPCP)

Adenosine-5'-[(β,γ)-methylene]triphosphate, Sodium salt

Cat. No.	Amount
NU-422-10	10 mg
NU-422-25	25 mg



Structural formula of AppCp

For general laboratory use.**Shipping:** shipped on gel packs**Storage Conditions:** store at -20 °C

Short term exposure (up to 1 week cumulative) to ambient temperature possible.

Shelf Life: 12 months after date of delivery**Molecular Formula:** C₁₁H₁₈N₅O₁₂P₃ (free acid)**Molecular Weight:** 505.21 g/mol (free acid)**Exact Mass:** 505.02 g/mol (free acid)**CAS#:** 7414-56-4**Purity:** ≥ 95 % (HPLC)**Form:** solid**Color:** white to off-white**Spectroscopic Properties:** λ_{\max} 259 nm, ϵ 15.4 L mmol⁻¹ cm⁻¹ (Tris-HCl pH 7.5)**Applications:**Conformational studies on complex with mevalonate diphosphate decarboxylase^[1]Structure of the complex with foylpolylglutamate synthetase^[2]Structure of complex with p90 ribosomal S6 kinases^[3]Crystal structure of complex with Ca²⁺-ATPase^[4]NMR-studies of complex with yeast hexokinase^[5]Agonistic ligand, mainly for nucleoside receptor A₁
Nucleosidephosphates stabilized against hydrolytic degradation can directly bind to nucleoside receptors.**Specific Ligands:**Tubulin^[6]Nonhydrolyzable ligand for P2X purinoreceptor^[7,8]**Selected References:**[1] Reuther *et al.* (2011) Backbone 1H, 13C, 15N NMR assignments of the unliganded and substrate ternary complex forms of mevalonate diphosphate decarboxylase from *Streptococcus pneumoniae*. *Biomol. NMR Assign.* **5** (1):11.[2] Young *et al.* (2008) Structures of *Mycobacterium tuberculosis* foylpolylglutamate synthase complexed with ADP and AMPPCP. *Acta Crystallogr D Biol Crystallogr.* **D64** (Pt 7):745.[3] Ikuta *et al.* (2007) Crystal structures of the N-terminal kinase domain of human RSK1 bound to three different ligands: Implications for the design of RSK1 specific inhibitors. *Protein Sci.* **16** (12):2626.[4] Picard *et al.* (2005) The average conformation at micromolar [Ca²⁺] of Ca²⁺-atpase with bound nucleotide differs from that adopted with the transition state analog ADP.ALfx or with AMPPCP under crystallization conditions at millimolar [Ca²⁺]. *J. Biol. Chem.* **280** (19):18745.[5] Maity *et al.* (2002) Structure of triphosphoryl nucleotide bound at the active site of yeast hexokinase: 1H-nuclear magnetic resonance study. *J. Protein Chem.* **21** (4):265.[6] Kubala (2006) ATP-binding to P-type ATPases as revealed by biochemical, spectroscopic, and crystallographic experiments. *Proteins.* **64** (1):1.[7] Trezise *et al.* (1995) The selective P2X purinoreceptor agonist, beta,gamma-methylene-L-adenosine 5'-triphosphate, discriminates between smooth muscle and neuronal P2X purinoreceptors. *Arch. Pharmacol.* **351** (6):603.O'Connor *et al.* (1990) Characterization of P2x-receptors in rabbit isolated ear artery. *Br. J. Pharmacol.* **101** (3):640.

**AppCp**

(AMPPCP)

Adenosine-5'-[(β,γ)-methylene]triphosphate, Sodium salt

Del Toro Duany *et al.* (2008) The reverse gyrase helicase-like domain is a nucleotide-dependent switch that is attenuated by the topoisomerase domain. *Nucleic Acids Research* **36** (18):5882.

Toyoshima *et al.* (2004) Crystal structure of the calcium pump with a bound ATP analogue. *Nature* **430**:529.

Mayer *et al.* (1991) Re-evaluation of the specificity of adenylyl (beta,gamma-methylene)diphosphonate as a substrate for adenylate cyclase. *Histochem J.* **23** (2):100.

Williams *et al.* (1986) Effects of purine nucleotides on the binding of [^3H]cyclopentyladenosine to adenosine A1-receptors in rat brain membranes. *J. Neurochem.* **47** (1):88.

Mayer *et al.* (1985) Specificity of cytochemical demonstration of adenylate cyclase in liver using adenylyl- (beta, gamma-methylene) diphosphate as substrate. *Histochemistry.* **82** (2):135.

Meghji *et al.* (1984) The effect of adenylyl compounds on the heart of the dogfish, *Scyliorhinus canicula*. *Comparative Biochem. and Physiol.Part C: Pharmacol., Toxicol.& Endocrin.* **77C** (2):295.

Meghji *et al.* (1983) The effect of adenylyl compounds on the heart of the axolotl (*Ambystema mexicanum*). *Comparative Biochem. and Physiol.Part C: Pharmacol., Toxicol.& Endocrin.* **76** (2):319.